Molecular Mechanisms and Therapeutic Targets in Multiple Myeloma

Dear Colleagues,

In recent years, the treatment approach for multiple myeloma has changed significantly, with several new drugs introduced for both upfront and relapse management. This progress has been promoted by deeper knowledge of the interplay of this disease’s pathophysiology, genetics, molecular mechanism, and microenvironment. Recognizing the intra- and inter-heterogenous nature of multiple myeloma is crucial to the continuation of research in this field. Moreover, with the recognition of cereblon E3 ligase modulation, improved understanding of the impact of genetic abnormalities and how to improve their prognosis, and the advent of monoclonal therapies in MM, the use of targeted therapy for multiple myeloma has become achievable. These achievements have paved the way for exploring newer approaches to personalized medicine.

This Special Issue aims to showcase innovative research focusing the molecular mechanisms of multiple myeloma and targeted therapies for treating it, offering a fresh perspective on standard-of-care approaches and therapeutic paradigms. We welcome submissions of original research and review articles. Topics of interest range from signaling pathways, epigenetic regulation, and extracellular vesicles to metabolic changes, the intricacies of the microenvironment, and the roles of established targets like proteasome, cereblon E3 ligase modulation, and CD38 inhibition. In addition, we are keen to highlight research providing insights into BCL-2 family proteins, MEK/BRAF inhibition, XPO1 inhibition, c-MYC overexpression, BCMA, and emerging monoclonal targets (such as GPRC5D and FcRH5).

Dr. Rui Bergantim
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

• multiple myeloma
• targeted therapy
• molecular mechanisms
• signaling pathways
• epigenetics
• extracellular vesicles
• microRNAs
• high-risk mechanisms
• microenvironment
• metabolic alterations
• extramedullary disease
• cereblon E3 ligase modulation
• BCL-2 family proteins
• c-MYC overexpression
• HDAC inhibitors
• BMCA
• MEK/BRAF
• nuclear export inhibitors
• monoclonal antibodies
• new monoclonal targets